Ribosomes interact with messenger
and transfer RNA to translate genetic information into a protein.
Modulating the interaction between the ribosome and messenger RNA has been established as a therapeutic approach to addressing a number of diseases.
Cystic fibrosis (CF), familial adenomatous polyposis (FAP),
epidermolysis bullosa (EB), Duchenne muscular dystrophy (DMD)
Colon cancer, pancreatic cancer
Zikani’s TURBO-ZM™ (Tuning the Ribosome with Zikani Molecules) is a proprietary platform that allows rapid synthesis of novel compounds that can be optimized to target the human ribosome in a disease specific manner. With TURBO-ZM™, we can design novel oral ribosome modulating agents (RMAs) that can be tuned to deliver specific results. Zikani has an expanding library of these novel oral RMAs that have demonstrated strong activity across a range of diseases.
Be orally delivered
at low efficacious
doses for humans
risks of other
Target specific diseases
Zikani has established the TURBO-ZM™ platform PoC
(activity and druggability) across multiple disease areas.
APC mutant familial